ATACs: Unique New Mode of Action to Fight Cancer

27th March 2023

FY 2022 Financial Results & Business Update
Safe Harbor

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of Heidelberg Pharma AG. This material may not be distributed within countries where it may violate applicable law.
Agenda

• Corporate Overview & Highlights

• ATAC Technology & Proprietary Projects

• Financials

• Outlook
Heidelberg Pharma – a Clinical Stage Company

**Our Company**

- ~110 employees
- Headquarters in Heidelberg area, Germany
- Listed on Frankfurt Stock Exchange: HPHA
- Clinical stage biotech
- Complete in-house research capabilities
- Cash reach until mid-2025 (as of March 2023)

**Our Mission**

- Provide new options in cancer therapy
- Overcome resistance mechanisms
- Kill dormant tumor cells
- Develop biomarker for patient stratification

**Our Approach**

- Inhibition of RNA Polymerase II
- Targeted delivery via antibodies (ADC technology)
- Use Amanitin as toxic payload (ATAC technology)
## Growing Pipeline of Proprietary and Partnered Programs

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDP-101</td>
<td>BCMA</td>
<td>Multiple Myeloma (DBCL/CLL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huadong (Asia)</td>
</tr>
<tr>
<td>HDP-102</td>
<td>CD37</td>
<td>NHL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huadong (Asia, option)</td>
</tr>
<tr>
<td>HDP-103</td>
<td>PSMA</td>
<td>Prostate cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huadong (Asia)</td>
</tr>
<tr>
<td>HDP-104</td>
<td>GCC</td>
<td>Gastrointestinal (e.g. CRC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huadong (Asia, option)</td>
</tr>
<tr>
<td>HDP-XX</td>
<td>n/a</td>
<td>Solid &amp; hematological malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Proprietary</td>
</tr>
</tbody>
</table>

## ATAC pipeline partners

<table>
<thead>
<tr>
<th>ATAC partners</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>MGTA-ATACs</td>
<td>CD117, CD45</td>
<td>HSCs, conditioning programs for blood cancers and genetic diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Magenta</td>
</tr>
<tr>
<td>TAK-ATAC</td>
<td>n/a</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Takeda</td>
</tr>
</tbody>
</table>

## Legacy assets

<table>
<thead>
<tr>
<th>Legacy assets</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLX250-CDx</td>
<td>CA-IX</td>
<td>Renal and urothelial carcinoma, TNBC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Telix</td>
</tr>
<tr>
<td>TLX250</td>
<td>CA-IX</td>
<td>Renal carcinoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Telix</td>
</tr>
<tr>
<td>RHB-107</td>
<td>CA-IX</td>
<td>Oncology/GI, Covid-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RedHill</td>
</tr>
<tr>
<td>LH011</td>
<td>Pancreatic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Link Health</td>
</tr>
</tbody>
</table>

*All programs stopped*
**Highlights 2022 – Corporate Update**

**Strategic partnership with Huadong Medicine (February/September 2022)**

Exclusive licensing agreement for Asia*
- Exclusive development and commercialization rights for HDP-101 and HDP-103; deal value: **up to USD 469 m + royalties**
- Exclusive option for HDP-102 and HDP-104; deal value: **up to USD 461 m + royalties**
- Next 2 ATAC candidates: Right of first negotiation (ROFN)

**Investment Agreement**
- Equity investment of **€ 105 m** in Heidelberg Pharma
- 2 seats in Supervisory Board

**ATAC Technology Collaborations**

**Research and option agreement for an ATAC with Chiome (July 2022):**
Couple amanitin to an antibody that targets CDCP1, expressed on many solid tumors

**License agreement for an ATAC with Takeda (September 2022):**
Worldwide exclusive license for an ATAC targeting a previously selected target molecule (not disclosed)

* People’s Republic of China, Hong Kong, Macao, Taiwan, South Korea, Indonesia, Singapore, The Philippines, Thailand, Bangladesh, Bhutan, Brunei, Myanmar, Cambodia, Laos, Malaysia, Maldives, Mongolia, Nepal and Vietnam; excludes Japan, India, Pakistan, Sri Lanka

© Heidelberg Pharma AG
Highlights 2022 – Proprietary ATAC Programs

HDP-101 – first-in-human study in Multiple Myeloma patients with a completely new mode of action
- First patient dosed (Feb 2022)
- Preliminary safety data presented at ASH Annual Meeting 2022 (Dec 2022)

Preclinical candidates HDP-102 and HDP-103 advanced during 2022
- Production of antibody material for toxicology testing completed
- Production of toxin linker in non-GMP and GMP quality to be used for GLP and clinical Phase I studies
- Further preclinical and toxicology studies carried out

HDP-104: new ATAC targeting guanylyl cyclase C (GCC) revealed Fall of 2022
- Indication: gastrointestinal tumors

New preclinical data from the ATAC technology platform presented at the AACR 2022 Annual Meeting showing...
- the synergy of using ATACs together with immune checkpoint inhibitors and
- indicating that repeated treatment with ATACs in preclinical models results in better tolerability without compromising efficacy.
Pivotal Phase III ZIRCON reported positive topline results with imaging agent TLX250-CDx in November 2022

**Accurate diagnosis of clear cell renal cell carcinoma (ccRCC) with TLX250-CDx (89Zr-DFO-girentuximab)**

- Global multicenter Ph III trial with 300 patients with renal masses
- Imaging compared to histology of surgically obtained tissue (standard of truth)

**Pivotal trial met all endpoints:**

- 86% sensitivity, 87% specificity and 93% positive predictive value
- 85% sensitivity and 89% specificity in detecting ccRCC in tumors <4 cm

**Next steps:**

- Filing for regulatory approval with the FDA and other agencies
- Telix plans with potential marketing approval and launch in 2024
- **Indication expansion:** Ongoing Ph I and II studies in bladder cancer and in triple-negative breast cancer
ATAC Technology & Proprietary Projects
Lead Program: HDP-101 in Multiple Myeloma

**Multiple Myeloma (MM)**

- 70,000 deaths annually
- Median survival ~47-110 months
- Characterized by the proliferation of single clone of plasma cells derived from B-cells
- BCMA (B-cell maturation antigen) overexpression and activation are associated with MM

**HDP-101: Anti-BCMA-ATAC**

- Targeted elimination of BCMA-containing cells with favorable preclinical toxicity profile
- Higher potency in cells with 17p deletions, which are associated with aggressive disease
- Clinical trial started in Feb 2022
- Phase I dose escalation study ongoing

Source: [healthcare-in-europe.com](http://healthcare-in-europe.com)  
Source: Heidelberg Pharma
First-in-Human Clinical Trial with an ATAC ongoing
HDP-101: anti-BCMA-ATAC for multiple myeloma

<table>
<thead>
<tr>
<th>2022</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FPI</strong></td>
<td><strong>Dose escalation</strong> in MM patients: up to 36 patients</td>
<td><strong>RP2D</strong></td>
<td><strong>BCMA naïve MM Del(17p) stratified</strong></td>
</tr>
<tr>
<td><strong>US</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trial sites active and enrolling</strong>:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• MD Anderson, Houston</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Emory University, Atlanta</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Mount Sinai Hospital, New York</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• University Hospital Heidelberg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• University Hospital Mainz</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• University Hospital Kiel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trial status</strong>:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Three patient cohorts (20, 30, and 60 µg/kg) completed so far, 8 patients in total</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Latest review by Safety Review Committee in March:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Treatment is safe and well-tolerated in these three cohorts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Continue dose escalation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Discussion of Magenta events: no indication that they were related to the ATAC platform</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Implementation of additional precautionary safety measures recommended to maximize the safety of the patients</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Further US and European sites currently being opened
Further ATAC Candidates: HDP-102, HDP-103 and HDP-104

**HDP-102: anti-CD37-ATAC**
- CD37 is overexpressed on B-cell lymphoma cells
- Specific indication of non-Hodgkin lymphoma (NHL)
- High prevalence of 17p deletion in NHL
- ASH (Dec 2021): High efficacy of anti-CD37-ATAC in Richter’s syndrome xenograft model

**HDP-103: anti-PSMA-ATAC**
- PSMA is overexpressed in nearly all cases of prostate cancer; limited expression in normal tissue
- Target indication is Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Prevalence of 17p deletion in mCRPC is 60%
- 17p biomarker has been validated preclinically for prostate cancer (Nature Commun. 2018 22:4394)

**HDP-104: anti-GCC-ATAC**
- Guanylyl cyclase C (GCC) is a transmembrane receptor protein (GUCY2C) for regulation of intestinal electrolyte homeostasis
- (Over-) Expressed in >95% of colorectal cancer, and in ~ 65% of esophageal, gastric, and pancreatic tumors
- Indication: gastrointestinal tumors
- Generating IP and Preparation for preclinical development

**Potential IND application in 2024 for HDP-102 and HDP-103**
## Profit and Loss 2022

<table>
<thead>
<tr>
<th>in € m</th>
<th>Guidance 10/2022</th>
<th>FYR 2022</th>
<th>FYR 2021</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue and other income</td>
<td>18.5 – 20.5</td>
<td>19.9</td>
<td>2.3</td>
<td>765%</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>35.0 – 39.0</td>
<td>37.0</td>
<td>27.9</td>
<td>33%</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>4.7</td>
<td>4.7</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>R&amp;D costs</td>
<td>26.4</td>
<td>18.7</td>
<td>41%</td>
<td></td>
</tr>
<tr>
<td>Administrative costs</td>
<td>4.8</td>
<td>4.0</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>Other expenses</td>
<td>1.1</td>
<td>0.5</td>
<td>120%</td>
<td></td>
</tr>
<tr>
<td>Operating result (EBIT)</td>
<td>(16.0) – (20.0)</td>
<td>17.2</td>
<td>25.6</td>
<td>-33%</td>
</tr>
<tr>
<td>Net loss for the period</td>
<td>19.7</td>
<td>26.1</td>
<td>-25%</td>
<td></td>
</tr>
</tbody>
</table>

- Financials in line with adjusted guidance
- Sales revenue significantly higher due to upfront payment by Huadong
- Operating expenses including depreciation and amortization increased principally because research and development costs increased in line with planning
- Net loss lower than 2021 due to higher sales revenue and lower operating expenses than originally planned
Balance Sheet and Cash 2022

Financings 2022

- €5 m shareholder loan from dievini in February 2022
- €80 m gross proceeds from rights issue in September 2022
  - Issue of 12.4 million new shares at €6.44
  - Huadong becomes 2nd largest shareholder (35%) by participation in rights issue and additional share purchase from dievini

<table>
<thead>
<tr>
<th>Assets (€ m)</th>
<th>30.11.2022</th>
<th>30.11.2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-current assets</td>
<td>12.7</td>
<td>12.7</td>
</tr>
<tr>
<td>Other current assets</td>
<td>6.6</td>
<td>2.9</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>81.3</td>
<td>6.1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>100.6</strong></td>
<td><strong>21.7</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity and liabilities (€ m)</th>
<th>30.11.2022</th>
<th>30.11.2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current liabilities</td>
<td>28.0</td>
<td>14.9</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>6.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Equity</td>
<td>66.6</td>
<td>6.7</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>100.6</strong></td>
<td><strong>21.7</strong></td>
</tr>
</tbody>
</table>

- Cash balance at 30th Nov. 2022: €81.3 m (2021: €6.1 m)
- Average cash usage per month €0.7 m (Guidance: €2.7 to 3.1 m; 2021: €2.3 m)
- Equity year-end 2022 increased to €66.6 m (2021: €6.7 m)
- Equity ratio was 66.3% (2021: 30.8%)
Outlook
### Next Steps Proprietary ATAC Pipeline
High Priority and Focus on HDP-101 to Advance Validation

#### HDP-101

**Phase I/IIa study in RRMM**
- Dose escalation ongoing, further study centers in Poland and Hungary
- Implementation of additional precautionary safety measures
- Next dose cohort will be opened with the added modifications
- Phase I completion in early 2024 and dose finding for Phase IIa
- Start Phase IIa part in 2024

#### HDP-102

**CD37-ATAC for NHL**
- Completion of preclinical and toxicological studies
- IND 2024

#### HDP-103

**PSMA-ATAC for prostate cancer**
- Completion of preclinical and toxicological studies
- IND 2024

#### HDP-104

**Guanylyl cyclase C (GCC)-ATAC for colorectal cancer**
- Focus on generating IP
- Preclinical start in preparation
### Guidance 2023

<table>
<thead>
<tr>
<th></th>
<th>Actual 2022</th>
<th>Guidance 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue and other income</td>
<td>19.9</td>
<td>7.0 to 10.0</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>37.0</td>
<td>37.0 to 41.0</td>
</tr>
<tr>
<td>Operating result (EBIT)</td>
<td>(17.2)</td>
<td>(28.5) to (32.5)</td>
</tr>
<tr>
<td>Funds required</td>
<td>8.9</td>
<td>32.5 to 36.5</td>
</tr>
<tr>
<td>Funds required per month</td>
<td>0.7</td>
<td>2.7 to 3.1</td>
</tr>
</tbody>
</table>

- Cash reach is secured until mid-2025 based on current budget planning
**Investment Summary**

A clinical-stage company with the goal of becoming a global ADC player

Disruptive first-in-humans mode of action provides high efficacy and potential for unique clinical advantages

Clinical lead program with best-in-class potential for indication with high medical need

Heidelberg PHARMA
Focused Cancer Therapies

Increased efficacy against certain aggressive tumors based on biomarker

Validated by international high-quality partnerships

Strategic partnership for Asia, fastest growing pharmaceutical market

High value potential with growing ATAC pipeline and attractive ADC environment
Q & A